An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Corcept Therapeutics